IXICO plc Extension of a 5 year contract (7886P)
September 05 2017 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 7886P
IXICO plc
05 September 2017
5 September 2017
IXICO plc
("IXICO" or the "Company")
Extension of a 5 year contract in a Phase II/III Alzheimer's
Disease clinical trial
with a top 10 global pharmaceutical company
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed an extension and
expansion to its largest existing contract, which was awarded in
August 2015, for a Phase II/III clinical trial contract in
Alzheimer's Disease. Consequently, the total contract value has
increased from US$6.8m to US$7.7m, of which US$1.0m has been
recognised to date. The contract term has been extended by eight
months to May 2024.
In this study IXICO utilises its expertise and proprietary
technology platform to collect, measure and monitor changes in
disease pathology of participants in the trial. The expansion
reflects the addition of additional image data standardisation and
collection services, which will be provided over the duration of
the study.
Giulio Cerroni, CEO of IXICO, commented
"We are delighted to announce an extension to this significant
existing agreement which reflects the opportunities we continue to
develop to enhance our privileged position as trusted partners, to
provide additional technology enabled services to our
pharmaceutical customers".
For further information please contact:
IXICO plc Tel: +44 20
Giulio Cerroni, Chief Executive 3763 7499
Officer
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield /James 7408 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway / Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTEAKNLELPXEFF
(END) Dow Jones Newswires
September 05, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024